Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited announced it will host a shareholder update webinar on October 31, 2025, to discuss its September Quarterly Activities Report and provide updates on the regulatory progress and clinical development of its lead asset, NUZ-001. This initiative reflects Neurizon’s commitment to transparent communication with stakeholders as it continues to advance its mission of delivering meaningful progress for those affected by neurodegenerative diseases.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, specifically targeting ALS, the most common form of motor neurone disease, with a strategy to accelerate access to effective treatments and explore broader applications.
YTD Price Performance: -17.65%
Average Trading Volume: 714,288
Technical Sentiment Signal: Sell
Current Market Cap: A$74.84M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.